A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer (Q36205086)

12 August 2017

A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer (English)

1 reference

12 August 2017

1 reference

Lee S Rosen

1

1 reference

12 August 2017

Herbert I Hurwitz

2

1 reference

12 August 2017

Michael K Wong

3

1 reference

12 August 2017

Jonathan Goldman

4

1 reference

12 August 2017

David S Mendelson

5

1 reference

12 August 2017

William D Figg

6

1 reference

12 August 2017

Shawn Spencer

7

1 reference

12 August 2017

Bonne J Adams

8

1 reference

12 August 2017

Delia Alvarez

9

1 reference

12 August 2017

Ben K Seon

10

1 reference

12 August 2017

Charles P Theuer

11

1 reference

12 August 2017

Bryan R Leigh

12

1 reference

12 August 2017

Michael S Gordon

13

1 reference

12 August 2017

language of work or name

English

0 references

publication date

5 July 2012

1 reference

12 August 2017

Clinical Cancer Research

1 reference

12 August 2017

18

1 reference

12 August 2017

17

1 reference

12 August 2017

4820-4829

1 reference

Positron emission tomography imaging of CD105 expression during tumor angiogenesis.

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432706

Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432706

Endoglin-targeted cancer therapy

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432706

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432706

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432706

Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432706

Sorafenib in advanced hepatocellular carcinoma

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432706

Unique aspects of supportive care using monoclonal antibodies in cancer treatment

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432706

Endoglin (CD105): a marker of tumor vasculature and potential target for therapy

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432706

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432706

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432706

Hereditary Haemorrhagic Telangiectasia (HHT): genetic and molecular aspects.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432706

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432706

Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432706

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432706

Angiogenesis in health and disease

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432706

CD105 is important for angiogenesis: evidence and potential applications

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432706

Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432706

Defective angiogenesis in mice lacking endoglin

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432706

Expression and structural features of endoglin (CD105), a transforming growth factor beta1 and beta3 binding protein, in human melanoma

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432706

Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432706

Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432706

Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3432706

Hereditary hemorrhagic telangiectasia

22 September 2018

1 reference

12 December 2020

Differential expression of endoglin on fetal and adult hematopoietic cells in human bone marrow

1 reference

12 December 2020

1 reference

12 December 2020

Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma

1 reference

12 December 2020

Long-term therapy with bevacizumab in hereditary hemorrhagic telangiectasia

1 reference

12 December 2020

[New guidelines to evaluate the response to treatment in solid tumors]

1 reference

12 December 2020

Identification of a tumor-initiating stem cell population in human renal carcinomas

1 reference

12 December 2020

10.1158/1078-0432.CCR-12-0098

Identifiers

DOI

1 reference

12 August 2017

1 reference

12 August 2017

1 reference